Letrozol Pentafarma

Letrozole, the active ingredient in Letrozol Pentafarma, is a aromatase inhibitor presented as a tablet for oral use. It treats hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozol Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Pentafarma is an aromatase inhibitor used in the management of hormone‑dependent breast cancer.

- Hormone receptor‑positive breast cancer (adjuvant setting): reduces risk of disease recurrence after surgery. - Hormone receptor‑positive metastatic breast cancer: slows tumor progression and extends survival. - Post‑surgical endocrine therapy: maintains low estrogen levels to prevent tumor regrowth.

Adverse reactions may occur with letrozole therapy.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: occasional throbbing pain.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated transaminases. - Osteoporotic fractures: increased risk of bone breaks. - Pulmonary embolism: sudden shortness of breath, chest pain. - Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty.

Before initiating letrozole, several safety considerations are recommended.

- Bone health monitoring: assess bone mineral density regularly. - Lipid profile assessment: check cholesterol levels periodically. - Liver function tests: evaluate hepatic enzymes before and during treatment. - Cardiovascular risk evaluation: use caution in patients with known heart disease. - Avoid use in premenopausal women: drug is ineffective before menopause. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Letrozole may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Estrogen replacement therapy: antagonizes letrozole's estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower plasma concentrations. - Tamoxifen: concurrent use can diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may enhance anticoagulant effect, increasing INR. - Statins: potential alteration of lipid‑lowering efficacy. - Certain SSRIs (e.g., fluoxetine): may affect estrogen metabolism and modify letrozole activity.